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Evaluation of medical therapy of ang ina
pectoris can be approached in many ways, but
the objectives remain the same: (1) to relieve
the acute attack of angina pectoris , (2) to prevent its recurrence , (3) to allow the patient to
lead a normal lifestyle or, at least, one that is
acceptable to him or her , and (4) to prevent
myocardial infarction.
Major problems are incurred when one attempts to evaluate the natural history of angina
pectoris with the effects of various treatments .
Angina pectoris is a subjective complaint and
therefore the response to therapy is also subjective. As angina frequently waxes and wanes ,
improvement of the patient's condition does not
necessarily indicate a direct correlation with
treatment, nor does the fact that a patient has
angiographically proven coronary artery disease
and c hest pain mean that the coronary lesion is
causing the patient 's complaint Furthermore,
many patients treated for angina pectoris who
were later catheterized demonstrated that, despite th e fact th at they had c lassical angina, upwards of 1 0% to 20% of them had insignificant
coronary artery disease. 1
Thus there are problems in defining the
c riteria by which to judge the patient's response
to medical therapy Electrocardiograms as well
as exercise stress testing may show false-positive as well as false-negative patterns. Despite
the fact that not all angiograph ically demonstrated lesions cause symptoms, coronary angiography remains the best method by which to
judge the etiology of the patient 's com plaint. In
serving as the standard by which to define the
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presence of coronary artery disease it also provides a basis for the determination of the effectiveness of both medical and surg ical interventions.
Wh en correlating th e natural history of
angina pectoris and its treatment to this standard , one should remember that there are different types of angina Basically, patients demonstrate either simple stable angina or unstable
angina -th e latter often being termed '' preinfarction angina " or intermediate syndrome.
After reviewing a number of c linical studies , it
becomes apparent that different investigators
have different definitions of the forms of the
ang ina they describe and hence these studies
are not always comparable. The prognosis of
ang ina varies with the form of angina being considered. In addition , when the true natural history of angina pectoris could have been studied-th a t is , be f o re m ed ica l or surgical
intervention was possible-arteriography was
not available. Al l of these factors have precluded th e exact determination of the effectiveness of medical therapy based on the true natural history of angina pecto ris. At the present
time , there is no means by which such a study
cou ld be done. Despite all the problems and
lack of exactitude, one can evaluate, to some
extent, how modern medical th erapy may or
may not help the patient reach the therapeutic
goals outlined above.
In approaching the medical management
of angina, one must be aware that not all angina
is the result primarily of coronary artery disease.
As mentioned earli er, there are other causes of
angina such as arrhythmias, severe anemias ,
aortic valve disease , hypertensive cardiovascular disease, and idiopathic hypertrophic subvalvular aortic stenosis which need to be ex-
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eluded or, if included, to be treated. In many
instances therapy (which may include surgery)
aimed at these particular abnormalities may alleviate the patient's angina and make the use of
specific antianginal drugs unnecessary.
The physician should first try to remove
any recognized cause of the angina. The next
step should be an attempt to change the patient 's lifestyle without turning the individual into
a cardiac cripple. The physician should advise
the patient to stop smoking , avoid situations
which might precipitate angina, avoid extreme
environmental hazards , lose weight if necessary , and switch to an appropriate diet to decrease, or possibly reverse the progression of
the atherosclerotic process. Participation in
physician-approved exercise programs may allow the patient to maintain an acceptable lifestyle with a minimum of pain. If the patient is unhappy with the changes in lifestyle or if the
angina persists, the physician must employ additional medical (nitroglycerin may have already
been prescribed) or surgical therapy.
To understand why certain drugs are used
for the relief of angina, one needs to understand
the pathophysiology of ischemia (Fig 1). An individual develops angina or ischemic pain (which
may be manifested by sudden death, angina
pectoris, myocardial infarction, or the intermediate syndrome) when the myocardial oxygen demand exceeds the myocardial oxygen
supply. Basically, medical therapy attempts to
decrease oxygen demand whereas surgical
therapy attempts to improve oxygen supply.
Medical therapy for noncoronary-arterydisease-i nd uced angina pectoris may also
involve changes in the myocardial oxygendemand. For instance, treatment of hypertension reduces intramyocardial tension and
thus decreases oxygen demand. Treatment
with digitalis of heart failure associated with
angina may decrease angina by lowering both
the ventricular volume and the heart rate, and
this, too, reduces oxygen demand; also, by
lowering the left ventricular end-diastolic pressure, coronary vascular resistance is theoretically decreased and the subendocardial oxygen
supply improved. Although digitalis increases
the contractile state , thus increasing oxygen demand, it is hoped that the abatement in heart
rate and ventricular volume will produce a
greater decrease in oxygen demand , thereby
relieving the angina.
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Cigarette smoking causes undesirable effects on both oxygen supply and oxygen demand; it increases the heart rate and causes
vasoconstriction, both of which increase oxygen demand , and it also decreases the oxygen
supply by shifting the oxygen hemoglobin dissociation curve so that hemoglobin releases oxygen less readily to the tissues. In addition,
smoking increases the carbon monoxide content of the blood, which is bound by hemoglobin
in preference to oxygen; this, too, decreases
the oxygen supply.
Treatment with certain drugs which can
reduce or alleviate the angina may be indicated.
Specific antianginal drugs include nitroglycerin ,
isosorbide di nitrate , topical nitroglycerin, propranolol and metoprolol.
The various nitrates decrease angina by
causing peripheral venous pooling, thus lowering the intraventricular volume which lessens
oxygen requirements. lntraventricular pressure
may also abate , thereby decreasing coronary
vascular resistance and theoretically improving
subendocardial blood flow. Nitrates may also
lower arterial blood pressure and , as a result,
effect a decrease in impedance to blood flow;
hence, less intraventricular tension will be necessary for blood to be ejected. Problems occasionally arise if a decrease in blood pressure
caused by nitrates produces reflex tachycardia
which in turn causes an increase in the contractile state of the myocardium. Both the increased heart rate and the increased contractility will increase oxygen demand and may
cause angina Furthermore, marked hypotension may develop with the administration of sublingual nitroglycerin which may decrease oxygen supply. However, these problems are
infrequent.
The broad beta-blocker, propranolol , and
the more specific beta-one-blocker, metoprolol,
both decrease oxygen demand 2 by decreasing
the heart rate, the force of myocardial contractility, and the systolic blood pressure . The
theoretical problems of beta-blockers causing
increased ventricular volume which in turn increases oxygen demand and left ventricular
end-diastolic pressure, thus producing increasing coronary resistance and decreasing oxygen
supply , is usually not of clinical significance.
Contraindications for the use of these drugs,
however, are very important. If the patient's
heart rate prior to institution of therapy is 45 or
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Fig 1-Schematic representation of determinants of myocardial oxygen demand and myocardial oxygen supply. When the demand is greater than the supply, angina may develop

50, beta-blockers should not be used or else
used with extreme caution. Insulin-dependent
diabetics who are poorly controlled or who are
unreliable, in general, are not candidates for
beta-blocking drugs. Propranolol should not be
used on pati ents with severe bronchospastic
disease. Metoprolol, being a more specifi c
beta-one-blocker, th eoretically should not cause
as many problems as propranolol, especially
with brochospastic disease; however, it may be
desirable to have these patients on a beta-one
agonist prior to the instituti on of metoprolol.
Though the dose of these various antianginal drugs will vary from individual to individual, a few broad guidelines can be set (Fig 2).
Nitroglycerin is usually the first anti-anginal drug
utilized. Sublingual nitroglycerin should be begun in the lowest dose possible and the first
dose should be given in th e physician's office
while the patient is seated to observe any untoward reactions. Some patients complain of severe headaches and a few may be intolerant of
the drug for this reason. The dose of nitroglycerin should be increased as necessary to
achieve control of the patient' s angina Sublingual nitroglycerin is not solely used for acute
anginal attacks but may also be given prophylactically to patients wh o routinely develop angina with certain situations such as climbing or
engaging in anxiety-producing confrontations.
If angina is frequent, if the patient cannot
tolerate the nitroglycerin or if it is advisable to
avoid using prophylactic nitroglycerin , then either th e long-acti ng nitrates or propranolol
should be used . Neither the long-acting nitrates
nor propranolol are effective in terminating the
acute anginal attack; lsordil®'s effect lasts
longer th an th e 1 5-minute changes induced by
nitroglycerin and is often better tolerated by the

patient. However, the duration of lsordil®'s action is variable, and is partially determined by
th e route of administration. Sublingual lsordil®
has a shorter onset of action than the oral form ,
but its effect lasts only 3 to 4 hours whereas
oral lsordil® may be given at 4- to 6-hour intervals . Topical nitroglycerin action lasts for from 4
to 6 hours.
The dose of su blingual lsordil® may vary ·
from 2. 5 mg up to 2 0 mg every 3 to 4 hours,
depending on the patient' s response. If one
uses oral lsordi l®, it is important to realize that
hig her dosages must be used compared to subli ngual lsordil® to produce the same hemodynamic effects; however, the use of oral lsordi l® may be preferred, as it is often better
tolerated by the patient. Though one often starts
with at least 1 0 mg of oral lsordil® every 6
hours, usually at least 2 0 mg every 6 hours is
necessary to achieve improvement. The dosage
of topical nitrog lycerin, like lsordil®, must be titrated by the patient's response. Its advantage is
that a single evening application may prevent
nocturn al angina and permit th e pati ent to sleep
through the night ; a major disadvantage is that ,
as a paste, it may be aesthetically unpleasing .
Topical nitroglycerin is usually applied in terms
of inches or fractions of an inch and its efficacy
is partially dependent upon the site of application- better absorption obtained when it is
applied above the waist -and the area over
which the paste is applied- the greater the
area, the better the absorption
All nitrates have the potential problem of
decreasing blood pressure and causing reflex
tachycardia. Patients can usually tolerate headache, although aspirin or acetominophen may
have to be added to the regimen.
Propranolol is an effective drug for treatHASTILLO MEDICAL MANAGEMENT OF ANGINA /
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Fig 2----Commonly used anti-anginal drugs.

ing angina and the best results appear to occur
in patients who have either an elevated blood
pressure or an increased heart rate prior to institution of the drug . In treating angina, one usually prescribes propranolol every 6 hours and
the total daily dose is at least 1 60 mg . The drug
is begun at a lower dose of 1 0 to 20 mg every 6
hours and increased every 2 to 3 days, depending on the patient 's response in terms of blood
pressure , heart rate and symptoms. One should
carefully evaluate the patient for the appearance of peripheral edema, rales, weight gain or
other evidence of heart failure . The end point
for increasing the propranolol varies: precipitation of congestive heart failure, alleviation of
symptoms, or a decrease in heart rate to less
than 50 beats per minute. In some patients, one
may have to stop the drug because of bronchospasm.
Metoprolol was recently introduced in the
United States but has been used in Europe for a
long time. It is quite similar to propranolol but
has less effect on beta-two receptors. It is therefore preferable for patients with lung disease.
Otherwise , the many side effects are similar to
those of propranolol. One must remember that
both propranolol and metoprolol are associated
with rebound angina if the drug is rapidly withdrawn from patients who have responded .
Equipotent dosages of propranolol and metoprolol are about 40 mg of propranolol and 50
mg metoprolol and appear to produce the same
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decrease in heart rate , reduction of angina pectoris, reduction of nitroglycerin consumption
and improvement in exercise tolerance testing .
In European studies, propranolol and metoprolol were given every eight hours, but in the
United States, administration of propranolol
every six hours is more common.
Specific studies with lsord il®, in which the
drug was continued for up to 5 to 6 months,
have shown sustained symptomatic relief in
terms of the decreased frequency of anginal attacks, the number of nitroglycerin tablets used
by the patient , and improved exercise tolerance. Other studies have shown that continued
administration of lsordil® does not interfere with
the patient 's usual response to sublingual nitroglycerin: it does not blunt hemodynamic effects
induced by nitroglycerin or the relief of angina
Similar results have been obtained with longterm studies of nitroglycerin ointment. One can
therefore conclude that there is good evidence
that lsordil® and topical nitroglycerin do cause
improvement in the patient's symptoms and
functional status both subjectively and objectively , possibly for several months. However,
none of these studies answer th e question '·'will
they prevent myocardial infarction and sudden
death?"
Propranolol and metoprolol have been
studied in a similar manner. In 1969, 3 patients
clinically defined as having angina pectoris
were further subdivided into those having coro-

nary artery disease as judged by coronary arteriography (50% occlusion of at least one coronary artery) or a demonstrated transmural
infarction , and a second group of patients with
clinical angina but negative coronary arteriograms. Successful response to propranolol was
defined by at least a 50% decrease in incidence of angina, a 50% decrease in the number of nitroglycerin tablets used , or loss of one
or more provoking factors of angina . Only 23%
of patients with clinical angina but without
proven coronary artery disease responded to
the drug ; the patients with proven coronary artery disease responded 86% of the time. Thus ,
without employing coronary arteriography one
could have concluded that propranolol was less
successful in the treatment of angina pectoris
than it really is. This study showed that the dose
of propranolol required for a favorable response
was 1 60 to 2 40 mg a day and that the response to the drug did not correlate with the
number of vessels involved or the severity of the
patient's pretreatment angina.
In 1976 another study4 attempted to show
that the pati ent 's response to propranolol appeared to affect mortality. Despite some loopholes the study did clearly indicate that patients
who failed to respond to medical management
appeared to have a worse prognosis than the
responders; these nonresponders are th erefore
the patients who are usually referred for surgery.
Most studies conclude that high doses of
propranolol clearly decrease the incidence of
angina and allow the patients to lead more normal lives. Other evidence has shown that exerc ise to lera nce a lso improves, alth ough if
metoprolol and propranolol are used , it is often
not angina that curtails the patient 's activity but
frequently a fatigue-like syndrom e; some studies have shown th at if the patient is maintained
on a combination of propranolol and isosorbide
dinitrate, exercise tolerance improves even

more. It would seem logical that as these two
drugs affect different determinants of oxygen
demand , a combination of th e two might be
more effective than either one used singly
In summary , one can clearly state that the
medical therapy of angina pectoris is better than
no th erapy at all and that some patients clearly
do obtain subjecti ve as well as objective improvement. However , one still cannot determine
whether or not there is clear improvement utilizing med ical therapy in terms of morta lity relative
to the natural history of the disease. There are
also limitations to the use of th e drugs and there
are c learly failures; these drugs do not halt progression of the underlying atherosclerotic process and therefore do not cure. The choice between medica l or su rgical therapy depends on
many factors which are often defined by angiography , determined by th e fai lure of whatever
the physician believes to be maximum medical
therapy , and commonly influenced by the local
surgeon 's skills. The patient as well as the physician has a profound influence on whether
medical or surgical therapy is ultimately used .
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